Axcella Health Inc. Stock News

Axcella Health Inc. (AXLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

Axcella Health Inc. (AXLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

Axcella Health (NASDAQ:AXLA) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address []

Zacks Investment Research upgraded shares of Axcella Health (NASDAQ:AXLA) from a hold rating to a buy rating in a research report sent to investors on Tuesday, Zacks.com reports. They currently have $3.25 price target on the stock. According to Zacks, Axcella Health Inc. is a biotechnology company. It is engaged in the research and development []

Zacks Investment Research lowered shares of Axcella Health (NASDAQ:AXLA) from a buy rating to a hold rating in a research note released on Monday, Zacks.com reports. According to Zacks, Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. []

Pluristem Therapeutics (NASDAQ:PSTI) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Volatility & Risk Pluristem Therapeutics has a beta of 2.25, indicating that its stock price []

Want to try an out-of-the-box approach? Tap five stocks, namely OMI, STKL, CASY, LAZY and AXLA, with increasing P/E ratios.

Zacks Investment Research upgraded shares of Axcella Health (NASDAQ:AXLA) from a hold rating to a buy rating in a report released on Friday morning, Zacks.com reports. They currently have $3.50 target price on the stock. According to Zacks, Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel []

Want to try an out-of-the-box approach? Tap five stocks, namely OMI, STKL, CASY, LAZY and AXLA, with increasing P/E ratios.

Axcella Health Inc. (NASDAQ:AXLA) Stock analysts at Piper Sandler boosted their FY2021 earnings per share estimates for Axcella Health in a note issued to investors on Wednesday, November 10th. Piper Sandler analyst Y. Rahimi now expects that the company will earn ($1.66) per share for the year, up from their previous estimate of ($1.72). []

Axcella Health (AXLA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Axcella Health Inc (NASDAQ: AXLA) has announced a new clinical program investigating AXA1125 as a potential treatment for patients with Long COVID. Symptoms last for months following recovery from

Image by Ousa Chea on Unsplash The clinical-stage biotech company Axcella (NASDAQ: AXLA) uses endogenous metabolic modulators (EMMs) to treat complex diseases, including liver conditions. One of its l

Axcella Health's (AXLA) CEO Bill Hinshaw on Q2 2021 Results - Earnings Call Transcript